Anticoagulation for AF in VHD

 Anticoagulation for Atrial Fibrillation in Valvular Heart Disease

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is a major risk factor for ischemic stroke. The presence of valvular heart disease (VHD) further increases the risk of thromboembolism, making appropriate anticoagulation a cornerstone of management. However, not all valvular lesions are treated the same way, and the choice between vitamin K antagonists and direct oral anticoagulants (DOACs) depends largely on the type of valve disease present.

---

Why Does AF Increase Stroke Risk?

In AF, ineffective atrial contraction leads to blood stasis, particularly within the left atrial appendage. This promotes thrombus formation, which can embolize to the cerebral circulation and cause stroke.

Patients with valvular heart disease often have:

Left atrial enlargement

Elevated left atrial pressure

Blood flow abnormalities

Increased atrial fibrosis

These factors further enhance the risk of thrombus formation.

---

Understanding “Valvular” and “Non-Valvular” AF

Historically, AF was classified as valvular or non-valvular. Modern guidelines have narrowed the definition of “valvular AF.”

Valvular AF Requiring Warfarin

The term primarily refers to:

1. Moderate-to-severe rheumatic mitral stenosis

2. Mechanical prosthetic heart valves

These patients require anticoagulation with Warfarin.

All Other Valve Diseases

These include:

Mitral regurgitation

Aortic stenosis

Aortic regurgitation

Tricuspid valve disease

Bioprosthetic valves

Prior valve repair

Transcatheter valve replacement

These conditions are generally managed similarly to non-valvular AF, and DOACs are usually preferred.

---

Rheumatic Mitral Stenosis and AF

Why Is the Risk So High?

Rheumatic mitral stenosis causes:

Marked left atrial enlargement

Severe blood stasis

Spontaneous echo contrast

High thromboembolic risk

Stroke risk may remain substantial even when the CHA₂DS₂-VASc score is low.

Recommended Anticoagulation

Lifelong Warfarin

Target INR typically 2.0–3.0

Role of DOACs

Current evidence does not support routine use of DOACs in moderate-to-severe rheumatic mitral stenosis. Warfarin remains the standard of care.

---

Mechanical Prosthetic Valves and AF

Mechanical valves are highly thrombogenic due to:

Artificial valve surfaces

Flow turbulence

Activation of coagulation pathways

Recommended Therapy

Lifelong Warfarin

INR target depends on valve type and position

Typical targets:

Valve Position Target INR

Mechanical Aortic Valve 2.5–3.0

Mechanical Mitral Valve 3.0

High-Risk Mechanical Valves 3.0–3.5

Why Not DOACs?

Clinical trials demonstrated inferior outcomes and increased thromboembolic complications with DOACs in mechanical valve patients. Therefore, they are contraindicated.

---

Mitral Regurgitation and AF

Mitral regurgitation often leads to:

Left atrial enlargement

AF development

Anticoagulation Strategy

Stroke prevention is based on the CHA₂DS₂-VASc score.

Preferred agents include:

Apixaban

Rivaroxaban

Dabigatran

Edoxaban

---

Aortic Stenosis and AF

AF frequently develops in advanced aortic stenosis due to:

Left ventricular hypertrophy

Diastolic dysfunction

Elevated left atrial pressure

Anticoagulation

Use CHA₂DS₂-VASc score for risk assessment

DOACs are generally preferred unless contraindicated

---

Aortic Regurgitation and AF

Although AF is less common than in mitral valve disease, anticoagulation follows standard AF recommendations.

Preferred Approach

Assess stroke risk using CHA₂DS₂-VASc

DOACs are preferred in eligible patients

---

Bioprosthetic Valves and AF

Bioprosthetic valves are less thrombogenic than mechanical valves.

Early Postoperative Period

For the first 3 months after surgery:

Anticoagulation often involves Warfarin depending on valve type and surgical preference.

Beyond 3 Months

For patients with AF:

DOACs are generally acceptable and often preferred.

---

Transcatheter Aortic Valve Replacement (TAVR)

AF is common after TAVR.

Patients Without AF

Routine anticoagulation is generally not indicated solely because of TAVR.

Patients With AF

Anticoagulation should be guided by AF indications:

Usually a DOAC

Warfarin if specific indications exist

---

Valve Repair and AF

Patients undergoing:

Mitral valve repair

Tricuspid valve repair

Annuloplasty procedures

can generally receive DOACs once postoperative anticoagulation requirements are completed.

---

Role of CHA₂DS₂-VASc Score

For most valve lesions other than rheumatic mitral stenosis and mechanical valves, anticoagulation decisions are guided by the CHA₂DS₂-VASc score.

Components

Risk Factor Points

Congestive heart failure 1

Hypertension 1

Age ≥75 years 2

Diabetes mellitus 1

Stroke/TIA/systemic embolism 2

Vascular disease 1

Age 65–74 years 1

Female sex 1

Higher scores indicate greater stroke risk and stronger indications for anticoagulation.

---

Choosing Between Warfarin and DOACs

Warfarin Preferred

Mechanical prosthetic valves

Moderate-to-severe rheumatic mitral stenosis

Certain special clinical situations

DOACs Preferred

Mitral regurgitation

Aortic stenosis

Aortic regurgitation

Tricuspid valve disease

Bioprosthetic valves (>3 months)

Prior valve repair

---

Practical Clinical Summary

Valve Condition Preferred Anticoagulant

Mechanical valve + AF Warfarin

Rheumatic MS + AF Warfarin

Mitral regurgitation + AF DOAC

Aortic stenosis + AF DOAC

Aortic regurgitation + AF DOAC

Tricuspid valve disease + AF DOAC

Bioprosthetic valve (>3 months) + AF DOAC

Valve repair + AF DOAC

---

Key Take-Home Messages

AF substantially increases stroke risk in patients with valvular heart disease.

Only two major conditions routinely require warfarin: mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis.

Most other valvular lesions can be managed with DOACs according to standard AF guidelines.

CHA₂DS₂-VASc scoring remains essential for risk stratification in the majority of valve disease patients.

Appropriate anticoagulation dramatically reduces the risk of stroke, systemic embolism, and cardiovascular morbidity in AF patients with valvular heart disease.